Fundación Jiménez Díaz - Comprehensive Lung Cancer Care

The Thoracic Oncology Unit at Fundación Jiménez Díaz, along with its 4H-network in Madrid (Hospital Universitario Rey Juan Carlos, Hospital Universitario General, Hospital Universitario Infanta Elena), offers specialized, multidisciplinary care for lung cancer and other thoracic malignancies. Our primary objective is to provide high-quality, individualized care of the patients This comprehensive approach encompasses diagnosis, screening, treatment, and follow-up, adhering to national and international clinical guidelines.

Precise diagnosis is achieved through advanced molecular and genomic techniques, including immunohistochemistry, NGS, and liquid biopsy. Patients receive tailored local and systemic treatments and have access to innovative therapies via a broad portfolio of clinical trials for non-small cell lung cancer (NSCLC), small-cell lung cancer (SCLC), and other thoracic cancers.

Multidisciplinary Approach:

A core component of the Thoracic Unit is its Multidisciplinary Tumour Board (MDT), comprising specialists from Medical Oncology, Radiation Oncology, Pneumology, Thoracic Surgery, Radiology/Interventional Radiology, Nuclear Medicine, Pathology, Molecular Biology, Palliative Care, and Geriatric Oncology. The extended MDT team include: psycho-oncology, nutrition, rehabilitation, and oncology nursing professionals. The MDT convenes weekly to collaboratively review and discuss every case, from initial suspicion to complex treatment decisions, including referrals from the RED 4H network and other hospitals. A dedicated Molecular Tumour Board also meets weekly to translate genomic findings into personalized therapeutic strategies.

Research and Innovation

The Thoracic Oncology team integrates clinical excellence with robust leadership in clinical and translational research. They actively participate in and coordinate numerous academic clinical trials (Phase I-III), providing patients’ access to innovative treatments not yet routinely available. The center has been a global pioneer in developing immunotherapy, chemo-immunotherapy, and targeted therapies for over a decade, contributing to pivotal trials in these areas. Currently, over 150 active clinical trials (Phases I-III) are recruiting patients.

Key research lines include:

• Molecular profiling of non-small cell lung cancer using next-generation sequencing, liquid biopsy in NSCLC
• Exploring new biomarkers usingin vivo PDX model studies in SCLC as Galectin-1 and therapeutic trials with Galectin-1 inhibitors and combinations with other drugs as lurbinectidin

Our findings have been published in high-impact journals, such as New England Journal of Medicine, Lancet Oncology, JAMA Oncology, and Journal of Clinical Oncology.

Leadership

The Thoracic Oncology Unit is led by Dr. Manuel Dómine, MD, PhD, Associate Head of Oncology at Fundación Jiménez Díaz and Head of Thoracic Oncology & Clinical Trials. Dr.Dómine is a renowned expert in thoracic oncology, with extensive experience in clinical care and research. His work focuses on the development of new therapeutic strategies and the coordination of clinical trials in lung cancer. You can view his academic contributions on his Google Scholar profile. https://scholar.google.com/citations?hl=en&user=BaPppicAAAAJ

ResearchGate+4X (formerly Twitter)+4Google Académico+4Google Académico+1Google Académico+1

Key Collaborations

We collaborate with prestigious institutions and consortia, including:

• School of Medicine – Universidad Autónoma de Madrid
• START, San Antonio (TX, USA).
• American Society of Clinical Oncology (ASCO), ASCO QOPI Certified Centre
• European Society for Medical Oncology (ESMO)
• Spanish Lung Cancer Group (GECP)
• European Thoracic Oncology Platform (ETOP)
• ECO Foundation
• Instituto de Salud Carlos III
• START (San Antonio, Texas, USA)
• Christie Hospital in Manchester (UK)

Our Commitment

By integrating clinical excellence, cutting-edge research, and a patient-cantered multidisciplinary approach, our Lung Cancer Unit is committed to delivering the best possible outcomes while continuously advancing the field of thoracic oncology.

E-mail: mdomine@fjd.es

Phone : 00 34 915504800

Web: www.fjd.es